---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-308781"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2025-12-05T23:59:59+00:00"
generated_at: "2026-05-16T14:15:33.077873+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Stoke and Biogen present data supporting zorevunersen's disease-modifying potential for Dravet syndrome

## Summary
- Propensity score weighted analysis shows statistically significant reductions in major motor seizure frequency at 6 months (70mg loading dose) vs natural history.
- Improvements in cognition and behavior (Vineland-3) at 18 months with 45mg dosing; durable effects through 24 months.
- EEG analysis reveals dose-dependent decrease in abnormal brain activity; reduction in EEG abnormality correlated with seizure reduction.
- Safety: 81 patients, >800 doses; CSF protein elevations in 42% (Phase 1/2a) and 86% (OLE) but no clinical manifestations; 3 unrelated deaths (2 SUDEP, 1 malnutrition).
- Data are consistent with endpoints in ongoing Phase 3 EMPEROR study (week 28 primary, 18-month secondary).

## SEC filing metadata
- accession: 0001193125-25-308781
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2025-12-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312525308781/0001193125-25-308781-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312525308781/d272524d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-308781
- JSON: https://secwatch.observer/filing/0001193125-25-308781.json
- Plain text: https://secwatch.observer/filing/0001193125-25-308781.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.